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K11 chainNF-κB is a transcription factor known to be involved in pleomorphic biological phenomena such as inﬂamma-
tion and immune responses. Abnormal activation of NF-κB has been reported in many pathological condi-
tions, including allergic and auto-inﬂammatory diseases and malignancies. Therefore, the NF-κB activation
pathway has been extensively studied and involvement of the ubiquitin conjugation system in the NF-κB ac-
tivation pathways has been shown. Also non-degradable roles of the ubiquitin system have been revealed,
recently. Several types of polyubiquitin chains exist and the type of chain seems to determine how
ubiquitinated proteins are regulated. Roles of non-degradable types of polyubiquitin chains such as K63, lin-
ear and K11 chains in NF-κB activation is one of the big issues in NF-κB research. Thus, this short article dis-
cusses the differential roles of those polyubiquitin chains in NF-κB activation. This article is part of a Special
Issue entitled: Ubiquitin–Proteasome System. Guest Editors: Thomas Sommer and Dieter H. Wolf.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Ubiquitin, a highly conserved globular protein of 76 amino acids
in eukaryotic kingdoms, is a protein-based post-translational modi-
ﬁer. The ubiquitin system was identiﬁed as part of an energy-
dependent degradation system, and the signiﬁcant roles played by
the ubiquitin-proteolytic pathway in biology and medicine are
well-documented [1,2]. The importance of the ubiquitin-proteolytic
pathway is realized through its timely and selective recognition of
speciﬁc substrates, which are then destined for degradation [3].
Timely and selective protein modiﬁcation is desirable not only for
degradation but also a crucial feature of other modes of protein reg-
ulation such as signal-induced protein activation [4]. As expected,
these non-degradation roles of the ubiquitin system were subse-
quently recognized and are now widely accepted [5,6]. The ubiquitin
conjugation system regulates functions of proteins by conjugating
polyubiquitin chains in most cases. There are several types of
polyubiquitin chains, and the type of polyubiquitin chain is thought
to determine the mode of regulation of the conjugated proteins
[5,6]. Although it has been believed that polyubiquitin chains are
generated via one of seven Lys residues within ubiquitin, we have
identiﬁed a new type of polyubiquitin chain, the linear polyubiquitintin–Proteasome System. Guest
rights reserved.chain, in which ubiquitin is linked via an N-terminal Met residue
rather than a Lys residue of another ubiquitin molecules [7]. Further
analysis revealed that linear polyubiquitination is involved in NF-κB
activation [8,9]. It has been well-established that the ubiquitin con-
jugation system is deeply involved in the NF-κB activation pathway.
This review will discuss recent advances in research on the involve-
ment of ubiquitination in the NF-κB activation pathways.
2. The canonical and alternative NF-κB activation pathways and
involvement of the ubiquitin proteolytic system in both pathways
NF-κB is a transcription factor that plays a central role in inﬂamma-
tory responses by inducing the expression of pro-inﬂammatory mole-
cules. Besides inﬂammation, NF-κB is also involved in a broad array of
biological phenomena including cell survival and innate and acquired
immune responses [10,11]. NF-κB is inactive in resting cells as it resides
in the cytoplasm bound to inhibitor proteins called inhibitors of NF-κBs
(IκBs), and is induced by various agents including inﬂammatory cyto-
kines. Since abnormal activation of NF-κB occurs in many pathological
conditions such as allergic and auto-inﬂammatory diseases and neo-
plasms, the NF-κB activation pathway has been extensively studied
[11–13]. NF-κB activation pathways are basically subdivided into two
distinct pathways, known as the canonical and alternative pathways,
and the ubiquitin mediated protein degradation system is involved in
both [14,15].
In the canonical activation pathway, the IKK (IκB kinase) complex,
which comprises IKK1, IKK2 and NF-κB essential modulator (NEMO),
is activated upon stimulationwith various agents such as inﬂammatory
cytokines or Toll-like receptor (TLR) ligands. The activated IKK phos-
phorylates speciﬁc Ser residues within IκBs [16] and phosphorylated
130 K. Iwai / Biochimica et Biophysica Acta 1843 (2014) 129–136IκBs are speciﬁcally recognized by ubiquitin ligase complex SCFβTrCPs to
generate polyubiquitin chains and degraded by the proteasome. NF-κB
is released from IκBs and translocates to the nucleus to induce the tran-
scription of target genes (Fig. 1) [10,11]. The alternative pathway is ac-
tivated by some TNF-receptor family proteins including CD40 and BAFF.
Upon stimulation, NIK, which is degraded via ubiquitination by cIAP
ubiquitin ligases in resting cells, is stabilized and phosphorylates IKKα.
Phosphorylated IKKα induces phosphorylation of NF-κB2/p100, which
forms a complexwith RelB. The RelB/p100 complex resides in cytoplasm
because C-terminal half of p100 possesses IκB-like function. Phosphory-
lated NF-κB2/p100 is ubiquitinated by SCFβTrCPs E3s followed by the pro-
cessing (partial degradation) to p52 by the proteasome, which allows
translocation of the resultant RelB/p52 heterodimer to the nucleus
(Fig. 2) [17]. Recently, it has been shown that NF-κB2/p100 is also
ubiquitinated by the SCFFbxw7 ubiquitin ligase in the nucleus [18]. How-
ever, the SCFFbxw7-mediated degradation of NF-κB2/p100 is suggested to
be involved in the down regulation of NF-κB activation, but not in the al-
ternative NF-κB activation.
The ubiquitin-proteolytic pathway plays a crucial role in both canon-
ical and alternative NF-κB activation pathways. However, the involve-
ment of different ubiquitin modiﬁcations, most of which exert a
non-degradable function, has been revealed in the canonical but not inFig. 1. The canonical NF-κB activation pathway. NF-κB (p65–p50 heterodimer in this ﬁgure) re
Upon binding to TNF-α, TRADD and RIP1 are recruited to the TNF-receptor 1 (TNFR1). TRADD t
receptor (IL-1R), which recruits IRAK1 and IRAK4 to the receptor. IRAK1 binds to TRAF6. The u
leading to canonical IKK activation, namely IKK2 phosphorylation. Phosphorylated IκBα is then
graded by the proteasome. Liberated NF-κB translocates to the nucleus and induces the exprethe alternative pathway [19]. Here Iwill focus on the role of the ubiquitin
system in the canonical NF-κB activation to highlight non-degradable
function of the ubiquitin conjugation system in signaling.
3. Involvement of different types of polyubiquitin chains in the
canonical NF-κB activation pathway
3.1. Importance of non-degradable function of the ubiquitin system in
NF-κB activation
As mentioned before, there exist several types of polyubiquitin
chains in cells [5]. Although polyubiquitin chains linked via Lys 48 of
ubiquitin (K48 chains) were shown to function as a degradation signal
[20], presence and function of other polyubiquitin chains has not been
convincingly shown except the involvement of Lys63-linked (K63)
chains in DNA repair in yeast [21]. Functions of other chains than K48
chains in signaling were ﬁrst reported in the canonical NF-κB activation
pathway, in which K63 chains were suggested to be involved. The re-
port by the James Chen's group was really a breakthrough in the
ubiquitin ﬁeld [22]. Extensive studies have been performed to dissect
the role of K63 chains in NF-κB signaling since then, which have con-
vincingly revealed the presence of the non-degradable function of thesides within the cytoplasm of resting cells in a form bound to the inhibitor protein, IκBα.
hen recruits TRAF2 and cIAPs. In the case of IL-1β signaling, MyD88 is recruited to the IL-1
biquitin ligase activities of TRAF2, TRAF6 and cIAPs are involved in the signaling cascade
conjugated with K48-linked polyubiquitin chains by the SCFβTrCPs ubiquitin ligase and de-
ssion of target genes.
Fig. 2. The alternative NF-κB activation pathway. Upon stimulation with BAFF, NIK, which is degraded via cIAP-mediated ubiquitination in resting cells, is stabilized and phosphorylates
IKK1. Phosphorylated IKK1 induces phosphorylation and ubiquitin-dependent processing (partial degradation) of NF-κB2/p100 to p52, which allows translocation of the RelB/p52
heterodimer to the nucleus.
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chains in NF-κB signaling have been published [24], the current hypoth-
esis of the roles of K63 chains in IL-1β- and TNF-α-induced canonical
NF-κB activation pathway will only be summarized here. Upon binding
IL-1β, in addition to adaptor molecules, the TRAF6 ubiquitin ligase is
recruited to the IL-1 receptor complex andK63 chains conjugatedmainly
onto TRAF6 itself and on IRAK1 recruit the TAK1–TAB1–TAB2/3 complex
and the IKK complex via K63-selective binding of TAB2/3 or NEMO,
respectively [19]. TAK1 then phosphorylates speciﬁc Ser residues (Ser
177 and Ser 181) of IKK2, which leads to the phosphorylation and degra-
dation of IκBs (Fig. 3) [25]. K63 chains are shown to be generated upon
stimulation with various agents including TNF-α besides IL-1β. When
stimulated with TNF-α in addition to adaptor molecules, ubiquitin li-
gases including TRAF2 and cIAPs are recruited to the TNF receptor 1
and K63 chains conjugated mainly onto RIP1, which are suggested to
be generated by cIAPs [19]. The K63 chains are suggested to recruit the
IKK and TAK1 complexes and activate the former. Recently, unanchored
K63 chains catalyzed by TRAF6 were proposed to be crucial for IKK acti-
vation [26] that highlighted the important role of K63-linked chains in
NF-κB activation. In these settings, K63 chains recruit signaling mole-
cules to the activated receptor complexes. However, the involvement
of K63-linked chains inNF-κB activation has been challenged. In cells iso-
lated fromKOmice of Ubc13, a crucial component of anUbc13–Uev1a E2
complex to generate K63 chains speciﬁcally [22], NF-κB nor MAPK acti-
vation mediated by TNF-α is not overtly affected [27]. Moreover, K63
chains are dispensable for TNF-α-, but not IL-1β-, induced canonical
NF-κB activation [28]. Thus, although K63 chains play crucial roles insignaling, they might be dispensable for the canonical NF-κB activation,
at least in some occasions including TNF-α stimulation.3.2. Newly discovered linear chains and their roles in NF-κB activation
The ubiquitin chains have been believed to be generated by conju-
gating C-terminal carboxyl groups of ubiquitin to ε-amino groups of
one of seven Lys residues of another ubiquitin [29]. However, genera-
tion of a new, different type of ubiquitin chain called the linear ubiquitin
chain, in which the C-terminal carboxyl groups of ubiquitin is conjugat-
ed to the α-amino group of N-terminus of another ubiquitin has been
reported [7]. Here, how the linear chains were discovered is discussed.
Although polyubiquitin chains are believed to be generated by the
repetitive functions of three enzymes E1, E2 and E3, molecular mech-
anisms underlying polyubiquitin chain generation have not been com-
pletely solved [30]. We have identiﬁed the ubiquitin ligase (E3)
complex composed of two RING–IBR–RING proteins HOIL-1L and
HOIP. HOIL-1L and HOIP possess multiple putative ubiquitin binding
sites (NZFs in HOIL-1L and HOIP) in addition to E2 binding sites
(Fig. 4). It was thus hypothesized that the ubiquitin ligase complex
recognizes ubiquitin as a substrate and conjugates ubiquitin onto it.
Further analyses revealed that it was the case and mass spectrometric
analyses showed that HOIL-1L–HOIP complex exclusively generates
linear polyubiquitin chains [7]. Although it has been suggested that E2
enzymes determine the type of polyubiquitin chain in the several Lys
linked chains [31] (E2 complexes containing Ubc13 (Ubc13–Uev1a
Fig. 3. The proposed role of K63 chains in canonical NF-κB activation. K63 chains generat-
ed upon stimulation by IL-1β recruit the TAK1–TAB1–TAB2/3 complex and the IKK com-
plex via the selective binding of TAB2/3 or NEMO to K63 chains, respectively. TAK1 then
phosphorylates IKK2, which leads to the phosphorylation and degradation of IκBs.
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the speciﬁcity of linear chains is determined by E3 [7].
During the course of seeking the physiological function, we found
that siRNA mediated suppression of HOIP, the catalytic subunit of
LUBAC and introduction of the catalytic inactive HOIP mutant
suppressed TNF-α-mediated of NF-κB activation, which conﬁrmed
that LUBAC seems involved in NF-κB activation [33]. Mice lacking
HOIL-1L, a regulatory component of LUBAC further provided solid evi-
dences of involvement of LUBAC-mediated linear polyubiquitination
in NF-κB signaling. TNF-α-induced nuclear localization of p65, a subunit
of NF-κB, is heavily impaired in primary hepatocytes isolated from
HOIL-1L knockout (KO) mice [33]. Moreover, TNF-α-induced IKK acti-
vation and expression of target genes of NF-κB are severely attenuated
in embryonic ﬁbroblasts (MEFs) from the HOIL-1L KO mice [33].Fig. 4. Schematic representation of LUBAC that comprisesHOIL-1L, HOIP and SHARPIN. LUBAC is
HOIP are the substrate-binding site and E3 active site, respectively. UBL; ubiquitin-like, NZF;NPl
UBA; ubiquitin-associated domains. Interaction between HOIL-1L UBL and HOIP UBA is involve
be involved in LUBAC formation but HOIP lacking NZF2, but not lacking UBA, does bind to SHAHowever, TNF-α-induced NF-κB activation is not completely
abolished in HOIL-1L KOmice [33]. Knocking-out ofmolecules essential
for NF-κB activation, such as NEMO or IKK2, is embryonic lethal in mice
[34–36], but HOIL-1L KO is not [33]. The expression of HOIP, which is a
catalytic subunit of the complex, was heavily decreased but not
completely absent in HOIL-1L KO cells [37], which prompt us to hypoth-
esize that HOIP may have another binding partner besides HOIL-1L.
SHARPIN, which C-terminus exhibits signiﬁcant homology with the
N-terminal half of HOIL-1L that is essential for binding to HOIP, has
been found (Fig. 4) [37–39]. SHARPIN has also been identiﬁed as a caus-
ative gene in chronic proliferative dermatitis in mice (cpdm) in 2007
and SHARPIN protein was not detected in cpdm cells [40,41]. Cpdm
mice are spontaneousmutantmice exhibiting chronic inﬂammation in-
cluding chronic dermatitis and immunodeﬁciency. However, the pre-
cise mechanism why loss of SHARPIN provokes these phenotypes in
cpdm mice had not been identiﬁed. Further analysis showed that
SHARPIN forms a complex with not only HOIP but also HOIL-1L,
namely SHARPIN formed the tertiary complex with HOIL-1L and HOIP.
The complex composed of HOIL-1L, HOIP and SHARPIN conjugates to
linear polyubiquitin chains and we designated the complex composed
of HOIL-1L, HOIP and SHARPIN as LUBAC (linear ubiquitin chain assem-
bly complex) [37–39]. So far, LUBAC is the only reported E3 known to
speciﬁcally generate linear chains [9]. In cells isolated from cpdm
mice, the lack of SHARPIN was found to reduce drastically the amount
of the other components of LUBAC, HOIL-1L and HOIP, by destabilizing
them, thereby attenuating canonical NF-κB activation induced by
TNF-α, CD40 or LT-βR [37–39]. Recently, loss-of-function mutation of
HOIL-1L provokes a fatal human inherited disorder characterized by
chronic autoinﬂammation, invasive bacterial infections and muscular
amylopectinosis [42]. Loss of HOIL-1L destabilizes the other two
components of LUBAC, thereby suppresses signal-inducedNF-κB activa-
tion in cells isolated from patients as observed in cells from HOIL-1L KO
mice [43]. However, no overt phenotypes have been reported in
HOIL-1L KO mice although signal-induced canonical NF-κB activation
is impaired [33]. Currently, the mechanism underlying phenotypical dif-
ference between HOIL-1L null mice and HOIL-1L null patients or cpdm
mice is unknown. Further precise analyses for HOIL-1L KO mice will be
needed to clarify it. Thus, loss of regulatory subunits of LUBAC suppresses
signal-induced canonical NF-κB activation and provokes diseases charac-
terized by auto-inﬂammatory and immunodeﬁciency phenotypes. The
current hypothesis for molecular mechanism underlying LUBAC-
mediated NF-κB activation is as follows: upon stimulation with agents
such as TNF-α, IL-1β, or TLR ligands, LUBAC recognizes and linearly
polyubiquitinates NEMO, which induces IKK activation and subsequent
degradation of IκBα (Fig. 5). Although linear polyubiquitination of
NEMO is suggested to be involved in IKK activation, further precise anal-
yseswill be deﬁnitely necessary to clarify themechanismunderlying IKK
activation by LUBAC-mediated linear polyubiquitination.
Although loss of SHARPIN or HOIL-1L attenuates the canonical
NF-κB activation, it is of note that canonical NF-κB activation is notcomposed ofHOIL-1L, HOIP and SHARPIN. The zincﬁnger andRING–IBR–RINGdomains of
4-type zincﬁnger, RING; really interesting newgene, IBR; in-betweenRING, ZF; zincﬁnger,
d in LUBAC formation. Interaction between HOIP NZF2 and SHARPIN UBL was suggested to
RPIN in cells.
Fig. 5. The proposed role of linear chains in canonical NF-κB activation. Upon stimula-
tion with TNF-α and IL-1β, LUBAC, which is composed of HOIL-1L, HOIP and SHARPIN,
recognizes and linearly polyubiquitinates NEMO, which leads to IKK activation and
subsequent degradation of IκBα.
133K. Iwai / Biochimica et Biophysica Acta 1843 (2014) 129–136completely abolished in cells lacking HOIL-1L or SHARPIN, possibly be-
cause residual LUBAC, composed of SHARPIN and HOIP or HOIL-1L and
HOIP, respectively, possesses linear polyubiquitination and NF-κB acti-
vation activity. This issue will be discussed later in the article.
3.3. Possible involvement of K11 chains in canonical NF-κB activation
K11 chains, which have been shown to be conjugated to the sub-
strates of the anaphase promoting complex E3, destined the conjugat-
ed proteins for degradation by the proteasome [44]. However, it has
been shown that K11 chains are also generated by the cIAP ubiquitin
ligases and conjugated to RIP1 and involved in the canonical NF-κB
activation upon TNF-α stimulation [45,46]. In the case of the NF-κB
pathway, K11 chains do not function as a degradation signal. Thus,
currently at least three different ubiquitin chains, K11, K63 and linear
chains, are known to be involved in signaling process leading to IKK
activation in a non-degradable manner.
4. Functional interplay of distinct non-degradable ubiquitin
chains in canonical NF-κB activation
Although involvement of K63, linear and K11 chains in canonical
NF-κB activation has been suggested, distinct roles played by each
chain in the canonical NF-κB activation have not been conclusively
addressed. Here I'd like to discuss roles of different chains in the canon-
ical IKK activation based on currently available knowledge. NEMO, an in-
dispensable subunit of the canonical IKK complex plays a key role in
ubiquitin-mediated activation of the canonical NF-κB pathway [47].
NEMO exhibits the ubiquitin-binding activity that is prerequisite for
IKK activation [48,49]. NEMO possesses two ubiquitin binding domains:
one is located in the middle part of the protein, referred to as the UBAN
domain [50], and the other is the C-terminal zincﬁnger (ZF) domain [51].
Mutations of amino acids in the UBAN domain or deletion of ZF cannot
restore signal-dependent activation of NF-κB in NEMO-deﬁcient cells
[51,52] conﬁrming the crucial roles of the ubiquitin-binding activity of
NEMO in IKK activation. However, the binding speciﬁcity of NEMO toubiquitin chains remains controversial. The UBAN domain is shown to
bind preferably to linear di-ubiquitin (1.4 μM) rather than K63 linked
di-ubiquitin (131 μM) [53]. Structural analyses conﬁrm high-afﬁnity
binding of the UBAN domain to linear di-ubiquitin [52,53]. However, in
the case of longer ubiquitin chains, NEMO containing both the UBAN
and ZF domains also bound to other types of ubiquitin chains, including
K11 and K63 linkages, albeit with lower afﬁnity than to linear linkages
[45,51].
In addition to ubiquitin binding activity, NEMO itself is also
ubiquitinated. NEMO is shown to be conjugated with K63-linked
chains [54–56]. NEMO is also identiﬁed as the major target for linear
polyubiquitination by LUBAC, which is involved in IKK activation as
described above [33,37–39]. Thus, both ubiquitin conjugation to
and recognition by NEMO seems to play crucial roles in the canonical
NF-κB activation. However, critical ubiquitin chains leading to the
canonical IKK activation cannot be identiﬁed only from biochemical
analyses.
Then, genetic evidences regarding signal-induced activation of canon-
ical NF-κB activation are discussed here. Although roles of K63 chains in
the canonical NF-κB activation have been well-documented, ablation of
Ubc13, the critical E2 enzymes for generating K63 chains does not overtly
affects TNF-α-mediated NF-κB nor MAP kinase activation. Although
NF-κB activation is not overtly affected, IL-1β-inducedMAPkinase activa-
tion was impaired in Ubc13 null cells [27]. Moreover, as mentioned be-
fore, K63 chains are dispensable for TNF-α-, but not IL-1β-induced
NF-κB activation [28]. In addition to genetic evidence using HOIL-1L or
SHARPIN-lacking cpdm MEFs, which showed that the linear chain is in-
volved in canonical NF-κB activation, it has been shown that siRNA-
mediated knockdown of HOIL-1L in SHARPIN-deﬁcient cpdm MEFs
attenuates IL-1β and TNF-α-mediated IκBα degradation almost com-
pletely [37]. These results suggested that LUBAC-mediated linear
polyubiquitination appears to play a central role in IKK activation
upon stimulation with TNF-α or IL-1β [33,37–39]. K11 chains are
shown to be generated by cIAP ubiquitin ligases, which are critical for
not only canonical NF-κB but also MAP kinases such as JNK and p38 ac-
tivation [57]. However, since cIAPs is reported to generate K48, K63 or
other type of ubiquitin chains besides K11 chains [45], precise roles of
K11 chains in NF-κB activation cannot be clariﬁed using the genetic
analyses. Collectively, current evidence suggested that K63 chains are
suggested to be involved in the activation of MAPKs as well as NF-κB
in IL-1β but not TNF-α stimulation. Linear chains are involved in
NF-κB in both TNF-α and IL-1β stimulation. The involvement of linear
chains in MAPK activation is still under investigation because some re-
port suggests that linear chains are not involved in MAPK activation
[37], but some other reports suggest marginal suppression on JNK acti-
vation by TNF-α and IL-1β [38,39]. K11 chains might be involved in
both MAPKs and NF-κB activation in TNF-α but not IL-1β signaling
since cIAPs are dispensable for IL-1β signaling.
Therefore, both K63 and linear chains are necessary for IL-1β-
mediated NF-κB activation [28,37–39] and K11 and linear chains seem
necessary for TNF-α-mediated NF-κB activation [37–39,45]. Since pro-
found suppression of linear chains generation by LUBAC selectively
suppresses NF-κB activation induced by both IL-1β and TNF-α al-
most completely [37], linear chains appear to play central roles in
IKK activation.
Next, mechanism underlying linear chain mediated activation of IKK
is discussed. The IKK complex is activated by phosphorylation of speciﬁc
Ser residues of IKK2 in the complex. Phosphorylation of kinases are me-
diated either by trans-autophosphorylation or by upstream kinases [58].
As mentioned before, linear chains are recognized by and conjugated to
NEMO. Thus, linear chains conjugated to NEMO can be recognized by
NEMO in another IKK complex, which induces multimerization of the
IKK complex and IKK2 phosphorylation by trans-autophosphorylation
(Fig. 6A) [8]. However, since binding of ubiquitin to theUBANdomain in-
duces conformational changes in NEMO [52], the positions of IKK1 and
IKK2 will be changed by linear chain recognition by NEMO, which
Fig. 6. The possible roles of the different polyubiquitin chains in IKK activation. (A) The linear chain conjugated onto NEMO can be recognized by NEMO of another IKK complex,
which induces multimerization of the IKK complex. Upon multimerization, IKK2 dimerizes and is phosphorylated by trans-autophosphorylation. (B) The linear chain conjugated
onto NEMO is recognized by the UBAN motif of another NEMOmolecule in the same IKK complex (it has been suggested that two NEMOmolecules exist in one IKK complex). Bind-
ing of the linear chain to the UBAN domain of NEMO induces conformational changes in NEMO, which affect the position of IKK1 and IKK2, leading to the phosphorylation of IKK2.
(C) A long K63 chain that is conjugated to components of the IL-1 receptor complex upon stimulation can be recognized by multiple NEMO proteins, which provokes
multimerization of the IKK complex leading to phosphorylation of IKK2. (D) A long K11 chain conjugated to RIP1 upon stimulation with TNF-α by the cIAP ubiquitin ligase can
be recognized by multiple NEMO proteins, which provokes multimerization of the IKK complex leading to phosphorylation of IKK2.
134 K. Iwai / Biochimica et Biophysica Acta 1843 (2014) 129–136leads to phosphorylation of IKK2 possibly by IKK1 (Fig. 6B) [8,52]. The
recently solved crystal structure of IKK2 shows that IKK2 possesses a di-
merization domain and dimerization-defective IKK2 mutants fail to be
activated [59], which favors that IKK is activated by linear chain-
induced dimerization.
Possible roles of K63 and K11 chains in NF-κB activation are also
discussed. The ligase activity of cIAPs, which generate K11 chains, is nec-
essary for recruitment of LUBAC to the TNF receptor complex [60]. Also,
LUBAC possesses ubiquitin binding activity including K63 chains [60,61].
Therefore, K63 and K11 chains might function to recruit LUBAC to the
IL-1 receptor and the TNF receptor complex, respectively (Fig. 7). Since
Ubc13 and cIAPs are involved in IL-1β- and TNF-α-induced activation
of MAPKs in addition to canonical NF-κB activation, respectively, thesechains may function in the upstream of the signaling cascades and play
a role to recruit LUBAC to the activated receptor complexes for IKK acti-
vation (Fig. 7). In addition toNEMO, RIP1,which is shown to be conjugat-
edwith K11, K48 and K63 chains, is also linearly ubiquitinated by LUBAC
upon TNF-α stimulation [39]. Since the ligase activity of LUBAC is neces-
sary for stabilizing the TNF receptor signaling complex [60], linear
polyubiquitination of RIP1 might be involved in stabilization of the TNF
signaling complex.
Although it might be plausible that LUBAC-mediated linear
polyubiquitination plays a central role in IKK activation, some other
mechanism(s) may collaterally exist in the canonical pathway for
NF-κB activation. K63 and K11 chains are conjugated to components
of the activated receptor complex upon stimulation with various
Fig. 7. The possible role of K63 and K11 chains in canonical NF-κB activation. K63 or K11
chains that are conjugated to components of the IL-1 receptor complex or RIP1 in the TNF
receptor complex, upon stimulation with IL-1β or TNF-α, respectively may recruit LUBAC
to the IL-1 receptor or the TNF receptor, respectively, and induce linear polyubiquitination
of NEMO. Linearly polyubiquitinated NEMO induces IKK2 phosphorylation.
135K. Iwai / Biochimica et Biophysica Acta 1843 (2014) 129–136agents. Since NEMO exhibits substantial afﬁnity to the long K11 and
K63 polyubiquitin chains, multiple NEMO proteins can recognize one
long polyubiquitin chain, which induces multimerization of the IKK
complex leading to phosphorylation of IKK2 (Fig. 6C, D) [45,51]. It
is also possible that upstream kinases such as TAK1 are recruited to
the activated receptor complex together with the IKK complex and
phosphorylated IKK2 (Fig. 3) [8]. TAK1, which forms a complex
with TAB1 and TAB2/TAB3 [62], is proposed as an upstream kinase
for IKK2 phosphorylation [15]. TAK1 is recruited to the stimulated
receptor complex by K63 chains because of the K63-speciﬁc binding
activity of TAB2 and TAB3.
5. Perspectives
Several mechanisms involved in the ubiquitin conjugation system
in the canonical and alternative NF-κB activation pathway were intro-
duced. I especially focused on the recent advance regarding involve-
ment of non-degradable ubiquitin chains in the canonical NF-κB
activation pathway, which activate the IKK complex by phosphoryla-
tion of IKK2 [11,16]. As discussed here, it might be the case that linear
chains play a major role in direct IKK activation upon TNF-α or IL-1β
stimulation. However, other ubiquitin chains may play a major role
upon stimulation with other molecules, such as the TCR [63]. Also,
even after stimulation with TNF-α or IL-1β, K11 or K63 ubiquitin
chains may function to activate IKK in some settings. A speciﬁc
ubiquitin chain exerts its distinct functions by being recognized by
ubiquitin binding domains that preferentially binds to the speciﬁc
chain over other chains [49,64]. Linear chains expressed in yeast
Saccharomyces cerevisiae, in which linear chains do not exist, function
as a degradation signal, albeit very weakly [65]. Because of the lack of
linear chains in the yeast, speciﬁc binding domains for linear chainsmay not exist. Thus, linear chains might function as a weak degrada-
tion signal by being recognized by ubiquitin-binding domains on the
proteasome that recognize K48 chains with low afﬁnity [66]. Thus,
TNF-α- or IL-1β-mediated IKK activation might not be completely
abolished in cells lacking synthesis of linear chains because NEMO ex-
hibits substantial afﬁnity to long K63 or K11 chains, which leads to
IKK activation. The ubiquitin conjugation system is a regulatory sys-
tem to regulate protein function [29]. Although the structures of
polyubiquitin chains differ from each other, there are many similari-
ties, and the ubiquitin binding domains that preferentially bind to
one chain may recognize other chains, albeit with lower afﬁnity.
Therefore, in the canonical NF-κB activation pathway, several chains
might be involved in direct activation of IKK and the signaling cas-
cades leading from stimulation to IKK activation.
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